Synaptive is transforming patient care with precision imaging, advanced navigation, and surgical robotics—unlocking better outcomes, reducing system costs, and enabling the AI-driven operating room of tomorrow.
Richter Inc. is selling the assets of Synaptive Medical Inc. following an Ontario Superior Court order dated May 13, 2026. The company is now soliciting qualified offers, with a deadline set for June 5, 2026. This process aims to transfer ownership of Synaptive’s assets to a new buyer.
Synaptive Medical has formed an advisory board to guide its clinical and technology strategy. The board will focus on advancing the company’s surgical visualization, navigation, and MRI platforms. This initiative aims to strengthen long-term development and innovation in medical imaging solutions.
Synaptive Medical secures a strategic investment to fuel growth and innovation in surgical care technologies. The company emerges from restructuring with a renewed focus on advancing transformative solutions for surgical procedures.
Synaptive Medical gains FDA clearance for **Modus IR**, a near-infrared fluorescence visualization module integrated into its **Modus X robotic exoscope**. The system supports neurosurgical, plastic, and ENT (ear, nose, throat) procedures by enhancing intraoperative imaging. The clearance expands Synaptive’s surgical robotics capabilities with advanced visualization tools.
